Who Generates Higher Gross Profit? Catalent, Inc. or Amneal Pharmaceuticals, Inc.

Catalent leads in gross profit over Amneal since 2014.

__timestampAmneal Pharmaceuticals, Inc.Catalent, Inc.
Wednesday, January 1, 2014449634000598600000
Thursday, January 1, 2015499226000615300000
Friday, January 1, 2016597455000587600000
Sunday, January 1, 2017526178000654600000
Monday, January 1, 2018716403000752600000
Tuesday, January 1, 2019352997000805100000
Wednesday, January 1, 2020628393000983300000
Friday, January 1, 20217689730001352000000
Saturday, January 1, 20227847080001640000000
Sunday, January 1, 20238205650001060000000
Monday, January 1, 2024953000000
Loading chart...

Data in motion

Catalent, Inc. vs. Amneal Pharmaceuticals, Inc.: A Battle of Gross Profits

In the competitive landscape of the pharmaceutical industry, Catalent, Inc. and Amneal Pharmaceuticals, Inc. have been vying for dominance in gross profit generation since 2014. Over the past decade, Catalent has consistently outperformed Amneal, boasting a 48% higher average gross profit. Notably, in 2022, Catalent's gross profit peaked at 1.64 billion, nearly doubling Amneal's 785 million. This trend highlights Catalent's strategic prowess in maximizing revenue streams and operational efficiency.

However, Amneal has shown resilience, with a steady increase in gross profit from 2014 to 2023, culminating in a 82% growth. Despite a dip in 2019, Amneal rebounded strongly, reflecting its adaptability in a volatile market. As we look to the future, the missing data for 2024 leaves room for speculation on whether Amneal can close the gap or if Catalent will continue its upward trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025